About the Company
We do not have any company description for Tenaya Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Tenaya Therapeutics, Inc.
Tenaya Therapeutics Reports Q2 2025 Financial Results
Tenaya Therapeutics, Inc. ( ($TNYA) ) has released its Q2 earnings. Here is a breakdown of the information Tenaya Therapeutics, Inc. presented to ...
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most ...
For the full year 2024, Tenaya Therapeutics disclosed a net loss of $111.1 million, or $1.31 per share, compared to $124.08 million in 2023.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation ...
Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have received a consensus rating of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports.
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 ...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 ...
Tenaya Therapeutics Publishes Positive Preclinical Data for TN ... - Nasdaq
Tenaya Therapeutics, Inc. has announced the publication of promising preclinical data for its gene therapy candidate, TN-201, designed to treat Myosin-Binding Protein C3 (MYBPC3)-associated ...
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 ...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and ...
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...
Tenaya Therapeutics Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are ...
This month, two insiders bought nearly $50 million worth of Tenaya Therapeutics shares at an average price of $0.70 per share. Currently, the stock trades at $0.70, having declined 51.05% year-to ...
Tenaya Therapeutics to Present Five Abstracts on Innovative Heart ...
Tenaya Therapeutics, Inc. announced that it will present five abstracts at the American Society of Gene and Cell Therapy's 28th Annual Meeting from May 13-17, 2025, in New Orleans.
Similar Companies
Loading the latest forecasts...